Unraveling the resistance mechanisms to PI3K/mTOR inhibition and PD-1 blockade in uterine leiomyosarcoma KU Leuven
Uterine leiomyosarcomas (uLMS) are rare and aggressive cancers
with only limited treatment options. Five-year overall survival ranges
between 16% and 57%, depending on the stage of the disease.
uLMS show substantial inter- and intra-tumor heterogeneity making
them difficult to treat. Due to this heterogeneity, not all patients
respond equally to the same treatments, underscoring the urgent
need for new ...